Finance
Genetics-focused biopharmaceutical company reports Q3 2004 financial results
Published in Gene Therapy Weekly, January 27th, 2005
Revenue for the third quarter was $11.0 million, compared to $12.8 million for the same period a year ago. For the first 9 months of 2004, revenue was $30.9 million, compared to $35.1 million for the first 9 months of 2003. These figures reflect the long-term, product development focus of the company's business strategy, as well as the timing of milestone payments.
At the close of the third quarter the company had $16.1 million in deferred research revenue, compared to $13.5 million at the close of the third quarter 2003....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-01-27)
More Articles from Gene Therapy Weekly
- Assisted Reproduction
Growth differentiation factor gene fragments treat porcine ovarian dysfunction - Cerebrovascular Disease
Homeobox D3 gene delivery initiates cerebral angiogenesis in mice - Gene Transfer
Jet injection and electroporation deliver plasmids to large muscles - Gene Transfer
Nucleotides targeting anti-apoptosis protein bind to erythroleukemia cells - Neurodegeneration
Beta-synuclein gene transfer protects mice from nervous system degeneration - Acute Myelogenous Leukemia
Clinical outcome not affected in pediatric AML patients with PTPN11 mutations - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
